SCHEMBL6496801

SCHEMBL6496801

COc1cccc(CNc2ccc3c(c2)Oc2ccccc2O3)c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.60
HIF1A Q16665 1/20 0.57
NPSR1 Q6W5P4 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 1/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 2/20 0.55
THRB P10828 1/20 0.55
PKM P14618 1/20 0.55
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 5/20 0.53
GAA P10253 5/20 0.53
MAPK1 P28482 3/20 0.53
POLB P06746 2/20 0.53
TSHR P16473 1/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
L3MBTL1 Q9Y468 5/20 0.53
TDP1 Q9NUW8 3/20 0.53
TP53 P04637 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483812 0.89 MEN1 (0.59) MAPTHIF1ANPSR1LMNANPC1
SCHEMBL6493342 0.86 MAPT (0.54) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL6485628 0.80 MAPT (0.56) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL3404174 0.78 ALDH1A1 (0.70) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL6485068 0.78 MAPT (0.56) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL6765385 0.77 MAPT (0.61) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL5713779 0.76 TUBB4A (0.64) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL6483853 0.76 MAPT (0.51) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL6528937 0.75 MAPT (0.56) MAPTHIF1ANPSR1SMN1; SMN2LMNA
SCHEMBL6482166 0.74 MEN1 (0.52) MAPTHIF1ANPSR1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885HIF1A 3185/4885NPSR1 1522/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885HIF1A 1519/4885NPSR1 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.